OC-0270: QoL and toxicity of HDR prostate brachytherapy as monotherapy 19Gy single fraction:phase II trial.

MLA

Gomez-Iturriaga, A., et al. “OC-0270: QoL and Toxicity of HDR Prostate Brachytherapy as Monotherapy 19Gy Single Fraction:Phase II Trial.” Radiotherapy & Oncology, vol. 123, May 2017, pp. S139–40. EBSCOhost, https://doi.org/10.1016/S0167-8140(17)30713-2.

APA

Gomez-Iturriaga, A., Casquero, F., Minguez, P., Espinosa, J., Bueso, A., Cacicedo, J., Fernandez, L., Pedraza, S., Garcia Escovedo, J., & Bilbao, P. (2017). OC-0270: QoL and toxicity of HDR prostate brachytherapy as monotherapy 19Gy single fraction:phase II trial. Radiotherapy & Oncology, 123, S139–S140. https://doi.org/10.1016/S0167-8140(17)30713-2

Chicago

Gomez-Iturriaga, A., F. Casquero, P. Minguez, J. Espinosa, A. Bueso, J. Cacicedo, L. Fernandez, S. Pedraza, J. Garcia Escovedo, and P. Bilbao. 2017. “OC-0270: QoL and Toxicity of HDR Prostate Brachytherapy as Monotherapy 19Gy Single Fraction:Phase II Trial.” Radiotherapy & Oncology 123 (May): S139–40. doi:10.1016/S0167-8140(17)30713-2.